Psoriasis, An Overview of its Pathogenesis and Available Treatment Modalities

Main Article Content

Zari Salahuddin
Muhammad Usman Ali Khan


Psoriasis is a chronic inflammatory and genetic disease that mainly involves skin with some complicated forms extending to other body systems. The disease is fairly common with genetic predisposition as one of the major etiology. It is known to occur as a result of immune system aberration involving helper T cells mainly and is thus treated on similar lines with most of the drugs belonging to immunomodulator class like steroids, calcineurin inhibitors, methotrexate and various others like retinoids. Disease pathology has a new area of research advancement focused on oxidative stress. It has been suggested that reactive oxygen species have a considerable role in the cascade of pathological features. The disease shows relapses and remissions seldom showing a remarkable or complete recovery. A therapy which can completely resolve the cosmetic and other important symptoms is still a food for research. The dimensions of research have also been inclined to nano particles as treatment options over past few years. In this review, our key objective is to highlight the complexity and clinical diversity of this multifaceted disorder, its pathogenesis and the potential of state of the art treatment options.

Article Details

How to Cite
Salahuddin, Z., Usman Ali Khan, M., & Akhtar, T. (2022). Psoriasis, An Overview of its Pathogenesis and Available Treatment Modalities. Albus Scientia, 2022(2), 1–5.
Review Articles


Alexis, A. F., & Blackcloud, P. (2014). Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances. The Journal of clinical and aesthetic dermatology, 7(11), 16–24.

Ayala-Fontánez, N., Soler, D. C., & McCormick, T. S. (2016). Current knowledge on psoriasis and autoimmune diseases. Psoriasis, 6, 7–32. DOI:

Barker J. N. (2001). Genetic aspects of psoriasis. Clinical and experimental dermatology, 26(4), 321–325. DOI:

Baz, K., Cimen, M. Y., Kokturk, A., Yazici, A. C., Eskandari, G., Ikizoglu, G., Api, H., & Atik, U. (2003). Oxidant / antioxidant status in patients with psoriasis. Yonsei medical journal, 44(6), 987–990. DOI:

Behnam, S. M., Behnam, S. E., & Koo, J. Y. (2005). Review of cyclosporine immunosuppressive safety data in dermatology patients after two decades of use. Journal of drugs in dermatology : JDD, 4(2), 189–194.

Bessar, H., Venditti, I., Benassi, L., Vaschieri, C., Azzoni, P., Pellacani, G., Magnoni, C., Botti, E., Casagrande, V., Federici, M., Costanzo, A., Fontana, L., Testa, G., Mostafa, F. F., Ibrahim, S. A., Russo, M. V., & Fratoddi, I. (2016). Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis. Colloids and surfaces. B, Biointerfaces, 141, 141–147. DOI:

Burden, A.D. and Kirby, B. (2016) Psoriasis and Related Disorders. In: Griffiths, C., Barker, J., Bleiker, T., Chalmers, R. and Creamer, D., Eds., Rook’s Textbook of Dermatology, 9th Edition, John Wiley & Sons, New Delhi, 1-64. DOI:

Capon F. (2017). The Genetic Basis of Psoriasis. International journal of molecular sciences, 18(12), 2526. DOI:

Chandran, V., & Raychaudhuri, S. P. (2010). Geoepidemiology and environmental factors of psoriasis and psoriatic arthritis. Journal of autoimmunity, 34(3), J314–J321. DOI:

Chuang, S. Y., Lin, C. H., Sung, C. T., & Fang, J. Y. (2018). Murine models of psoriasis and their usefulness for drug discovery. Expert opinion on drug discovery, 13(6), 551–562. DOI:

Danielsen, K., Olsen, A. O., Wilsgaard, T., & Furberg, A. S. (2013). Is the prevalence of psoriasis increasing? A 30-year follow-up of a population-based cohort. The British journal of dermatology, 168(6), 1303–1310. DOI:

Das, R. P., Jain, A. K., & Ramesh, V. (2009). Current concepts in the pathogenesis of psoriasis. Indian journal of dermatology, 54(1), 7–12. DOI:

Emre, S., Metin, A., Demirseren, D. D., Kilic, S., Isikoglu, S., & Erel, O. (2013). The relationship between oxidative stress, smoking and the clinical severity of psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV, 27(3), e370–e375. DOI:

Imafuku, S., Zheng, M., Tada, Y., Zhang, X., Theng, C., Thevarajah, S., Zhao, Y., & Song, H. J. (2018). Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. The Journal of dermatology, 45(7), 805–811. DOI:

Kadam, D. P., Suryakar, A. N., Ankush, R. D., Kadam, C. Y., & Deshpande, K. H. (2010). Role of oxidative stress in various stages of psoriasis. Indian journal of clinical biochemistry : IJCB, 25(4), 388–392. DOI:

Kim, J. S., Kuk, E., Yu, K. N., Kim, J. H., Park, S. J., Lee, H. J., Kim, S. H., Park, Y. K., Park, Y. H., Hwang, C. Y., Kim, Y. K., Lee, Y. S., Jeong, D. H., & Cho, M. H. (2007). Antimicrobial effects of silver nanoparticles. Nanomedicine : nanotechnology, biology, and medicine, 3(1), 95–101. DOI:

Lin, X., & Huang, T. (2016). Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free radical research, 50(6), 585–595. DOI:

Lowes, M. A., Suárez-Fariñas, M., & Krueger, J. G. (2014). Immunology of psoriasis. Annual review of immunology, 32, 227–255. DOI:

Michalek, I. M., Loring, B., & John, S. M. (2017). A systematic review of worldwide epidemiology of psoriasis. Journal of the European Academy of Dermatology and Venereology : JEADV, 31(2), 205–212. DOI:

Nickoloff, B. J., Schröder, J. M., von den Driesch, P., Raychaudhuri, S. P., Farber, E. M., Boehncke, W. H., Morhenn, V. B., Rosenberg, E. W., Schön, M. P., & Holick, M. F. (2000). Is psoriasis a T-cell disease?. Experimental dermatology, 9(5), 359–375. DOI:

Nijsten, T., Margolis, D. J., Feldman, S. R., Rolstad, T., & Stern, R. S. (2005). Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. Journal of the American Academy of Dermatology, 52(3 Pt 1), 434–444. DOI:

Panich, U., Sittithumcharee, G., Rathviboon, N., & Jirawatnotai, S. (2016). Ultraviolet Radiation-Induced Skin Aging: The Role of DNA Damage and Oxidative Stress in Epidermal Stem Cell Damage Mediated Skin Aging. Stem cells international, 2016, 7370642. DOI:

Parisi, R., Symmons, D. P., Griffiths, C. E., Ashcroft, D. M., & Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team (2013). Global epidemiology of psoriasis: a systematic review of incidence and prevalence. The Journal of investigative dermatology, 133(2), 377–385. DOI:

Paul, C., Gallini, A., Maza, A., Montaudié, H., Sbidian, E., Aractingi, S., Aubin, F., Bachelez, H., Cribier, B., Joly, P., Jullien, D., Le Maître, M., Misery, L., Richard, M. A., & Ortonne, J. P. (2011). Evidence-based recommendations on conventional systemic treatments in psoriasis: systematic review and expert opinion of a panel of dermatologists. Journal of the European Academy of Dermatology and Venereology : JEADV, 25 Suppl 2, 2–11. DOI:

Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017). Psoriatic Arthritis. The New England journal of medicine, 376(10), 957–970. DOI:

Schön, M. P., & Erpenbeck, L. (2018). The Interleukin-23/Interleukin-17 Axis Links Adaptive and Innate Immunity in Psoriasis. Frontiers in immunology, 9, 1323. DOI:

Sikar Aktürk, A., Özdoğan, H. K., Bayramgürler, D., Çekmen, M. B., Bilen, N., & Kıran, R. (2012). Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. Journal of the European Academy of Dermatology and Venereology : JEADV, 26(7), 833–837. DOI:

Sonawane, R., Harde, H., Katariya, M., Agrawal, S., & Jain, S. (2014). Solid lipid nanoparticles-loaded topical gel containing combination drugs: an approach to offset psoriasis. Expert opinion on drug delivery, 11(12), 1833–1847. DOI:

Syed, Z. U., & Khachemoune, A. (2011). Inverse psoriasis: case presentation and review. American journal of clinical dermatology, 12(2), 143–146. DOI:

Szentkereszty-Kovács, Z., Gáspár, K., Szegedi, A., Kemény, L., Kovács, D., & Törőcsik, D. (2021). Alcohol in Psoriasis-From Bench to Bedside. International journal of molecular sciences, 22(9), 4987. DOI:

Talamonti, M., Botti, E., Galluzzo, M., Teoli, M., Spallone, G., Bavetta, M., Chimenti, S., & Costanzo, A. (2013). Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. The British journal of dermatology, 169(2), 458–463. DOI:

Tonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., McClanahan, T. K., Blumenschein, W. M., Qin, J. Z., Xin, H., Oldham, E., Kastelein, R., Nickoloff, B. J., & Nestle, F. O. (2010). Cutting edge: A critical functional role for IL-23 in psoriasis. Journal of immunology (Baltimore, Md.: 1950), 185(10), 5688–5691. DOI: